The Value of Biosimilars in the Treatment of IBD: Frequently Asked Questions

The Value of Biosimilars in the Treatment of IBD: Frequently Asked Questions is organized by Medical Communications Media (MCM), Inc. 

Release Date: May-03-19
Credit Expiration Date: May-03-20

Accreditation:
Accme Credit Designation Statement: 
Albert Einstein College Of Medicine Designates This Enduring Material For A Maximum Of  0.5 Ama Pra Category 1 Credit.

Description:
Biosimilars offer additional treatment options for patients with IBD. In this activity, faculty will review the role of biosimilars in the management of IBD and answer learner questions from the previous activity (see "Related Programs" above).

Learning Objectives:
Upon completion of this educational activity, the participant should be able to:
• Describe how biosimilars are similar to and different from their originator biologic.
• Identify biosimilars approved for the treatment of patients with IBD.
• Discuss how the use of biosimilars contributes to value-based care.

Additional details will be posted as soon as information is available.